Romosozumab for treating severe osteoporosis

2.1 Romosozumab (EVENITY, UCB) is indicated for 'the treatment of severe osteoporosis in postmenopausal women at high risk of fracture'.

2.2 The dosage schedule is available in the summary of product characteristics for romosozumab.

2.3 The price for romosozumab is £427.75 for 2 pre-filled pens administered subcutaneously as a single monthly dose (BNF online, accessed October 2021). The company has a commercial arrangement. This makes romosozumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.